Current American guidelines from the National Kidney Foundation and the National Lipid Association have issued recommendations for the cautious use of fibrates in patients with chronic kidney disease.

Thus, a fibrate (fenofibrate) was added to the therapy. The study lasted 12 months. Patients: Forty-five patients (mean age: 58.9 ± 11.3 years) with primary mixed hyperlipidaemia who showed a ...